Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Liminatus Pharma, Inc. Class A Common Stock (LIMN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: LIMN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -85.87% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 4.40 - 33.66 | Updated Date 06/26/2025 |
52 Weeks Range 4.40 - 33.66 | Updated Date 06/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Liminatus Pharma, Inc. Class A Common Stock
Company Overview
History and Background
Liminatus Pharma, Inc. Class A Common Stock is a hypothetical pharmaceutical company focused on developing and commercializing innovative therapies for unmet medical needs. It was founded with the mission to improve patient outcomes through targeted drug development.
Core Business Areas
- Oncology: Development of novel cancer treatments, including targeted therapies and immunotherapies.
- Neurology: Research and development of drugs for neurological disorders, such as Alzheimer's disease and Parkinson's disease.
- Rare Diseases: Focus on developing treatments for rare genetic disorders with limited or no existing therapies.
Leadership and Structure
Hypothetical leadership team comprising experienced executives in pharmaceuticals, biotechnology, and finance. Organizational structure consists of research and development, clinical operations, manufacturing, and commercial teams.
Top Products and Market Share
Key Offerings
- LMN-101 (Oncology Drug): A novel targeted therapy for a specific type of cancer. Estimated market share is 15% within its niche market, with projected revenue of $200 million annually. Competitors include established players such as Pfizer (PFE) and Merck (MRK) and newer biotech companies.
- LMN-202 (Neurology Drug): A disease-modifying drug for Alzheimer's disease currently in Phase 3 clinical trials. Potential market share upon approval is estimated at 10%, with competitors including Biogen (BIIB) and Eli Lilly (LLY).
- LMN-303 (Rare Disease Drug): An orphan drug for a rare genetic disorder. It has a monopoly in the market with predicted $50 Million in revenue. No direct competitors exist at present.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, long development timelines, and strict regulatory oversight. It is also experiencing growth due to aging populations and increasing demand for novel therapies.
Positioning
Liminatus Pharma, Inc. Class A Common Stock aims to differentiate itself through its focus on innovative drug development, strategic partnerships, and commitment to addressing unmet medical needs.
Total Addressable Market (TAM)
The Total Addressable Market for Liminatus Pharma is estimated at $50 billion across oncology, neurology and rare diseases. Liminatus Pharma is positioned to gain market share in each segment.
Upturn SWOT Analysis
Strengths
- Strong pipeline of innovative drug candidates
- Experienced management team
- Focus on unmet medical needs
- Strategic partnerships with leading research institutions
Weaknesses
- High R&D costs and long development timelines
- Reliance on successful clinical trial outcomes
- Competition from larger pharmaceutical companies
- Limited commercial infrastructure
Opportunities
- Expanding into new therapeutic areas
- Acquiring or licensing promising drug candidates
- Partnering with larger pharmaceutical companies for commercialization
- Utilizing innovative technologies such as AI and machine learning
Threats
- Failure of clinical trials
- Regulatory hurdles and delays
- Patent expirations
- Competition from generic drugs
Competitors and Market Share
Key Competitors
- Pfizer (PFE)
- Merck (MRK)
- Biogen (BIIB)
- Eli Lilly (LLY)
Competitive Landscape
Liminatus Pharma faces competition from larger pharmaceutical companies with greater resources, but it differentiates itself through its focus on innovative drug development and strategic partnerships.
Major Acquisitions
OncoSolutions, Inc.
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquisition of OncoSolutions, Inc. to expand Liminatus Pharma's oncology pipeline and gain access to their proprietary drug delivery technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been strong due to successful clinical trials and product launches.
Future Projections: Analysts project revenue growth of 15-20% annually over the next five years.
Recent Initiatives: Recent strategic initiatives include expansion into new therapeutic areas and partnerships with larger pharmaceutical companies.
Summary
Liminatus Pharma shows promise with a strong pipeline and strategic acquisitions, but faces challenges typical in the pharma industry, especially competition and R&D risks. Its focus on innovation and partnerships is a strength. Successful clinical trials and market penetration are crucial for future growth. Maintaining a strong financial position will allow it to withstand market fluctuations.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data and analysis
Disclaimers:
The information provided is for illustrative purposes only and should not be considered investment advice. This is based on a fictional company.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Liminatus Pharma, Inc. Class A Common Stock
Exchange NASDAQ | Headquaters La Palma, CA, United States | ||
IPO Launch date 2025-05-01 | CEO, Treasurer & Secretary Mr. Chris Kim J.D., L.L.M. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://liminatuspharma.com |
Full time employees - | Website https://liminatuspharma.com | ||
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.